In addition, combination of DNMT inhibitors and PARP inhibitors promotes the accumulation of reactive oxygen species (ROS), thereby sensitizing breast and ovarian cancer cells to PARP inhibitors in a ROS-cAMP/PKA-dependent manner [45]. Here, DNMT1 is linked to ovarian carcinoma.